Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2017
Jun. 30, 2017
Current assets:    
Cash $ 5,916 $ 8,088
Accounts receivable - trade 260 175
Work in process 0 26
Prepaid expenses and other current assets 206 283
Total Current Assets 6,382 8,572
Fixed assets, net of accumulated depreciation 25,268 25,589
Intangible assets, net of accumulated amortization 1,757 1,823
Security deposit 26 26
Total Assets 33,433 36,010
Current liabilities:    
Accounts payable (related party of $56 and $87 as of September 30, 2017 and June 30, 2017, respectively) 596 749
Accrued expenses (related party of $778 and $650 as of September 30, 2017 and June 30, 2017, respectively) 1,047 924
Capital lease obligation - current portion 187 183
Deferred revenue 276 157
Total Current Liabilities 2,106 2,013
Capital lease obligation - net of current portion 25,034 25,082
Total Liabilities 27,140 27,095
Commitments and Contingencies
iBio, Inc. Stockholders’ Equity:    
Preferred stock - $0.001 par value; 1,000,000 shares authorized; 1 share issued and outstanding as of both September 30, 2017 and June 30, 2017 0 0
Common stock - $0.001 par value; 175,000,000 shares authorized; 92,818,510 and 89,118,510 shares issued and outstanding as of September 30, 2017 and June 30, 2017, respectively 93 89
Additional paid-in capital 82,178 80,977
Accumulated other comprehensive loss (29) (29)
Accumulated deficit (75,949) (72,123)
Total iBio, Inc. Stockholders’ Equity 6,293 8,914
Noncontrolling interest 0 1
Total Equity 6,293 8,915
Total Liabilities and Equity $ 33,433 $ 36,010